BioArctic Reports Record 2025 Growth, Partners with Novartis on Brain Transporter Tech
BioArctic AB recorded record 2025 results driven by expanded Parkinson’s and Huntington’s disease programs. It established a global collaboration with Novartis on its brain transporter technology after Lekembi generated over $500 million in sales across 53 countries.
1. BioArctic’s Record 2025 Performance
BioArctic AB delivered record financial results in 2025, marking transformative growth across its Parkinson’s and Huntington’s disease programs. Lekembi, its Alzheimer’s therapy, achieved over $500 million in global sales and received approval in 53 countries, driving revenue momentum.
2. Strategic Collaboration with Novartis
The company signed a global collaboration with Novartis to apply its brain transporter technology for antibody delivery into the brain. This deal follows similar partnerships with other pharmaceutical leaders and aims to accelerate development of novel CNS therapeutics.
3. Implications and Uncertainties for Novartis
For Novartis, access to the brain transporter platform could enhance its neurology pipeline, offering new modalities for challenging CNS targets. However, details on financial commitments, clinical milestones and timelines remain undisclosed, creating uncertainty around near-term valuation impact.